BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 3
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 27
• 28
• 29
• 30
• 31

• 

  Dan Samorodnitsky

  January 13, 2025
• 

  Dan Samorodnitsky

  Dan Samorodnitsky is the news editor at BioSpace. You can reach him at dan.samorodnitsky@biospace.com.
• 

  Regulatory

  Keytruda and Opdivo Scrutiny Highlights FDA’s Evolving Biomarker Focus

  An FDA committee’s September 2024 vote to limit the use of Merck’s Keytruda and BMS’ Opdivo in stomach and esophageal cancers based on PD-L1 expression levels reflects an emerging trend that leverages ever-maturing datasets.

  January 13, 2025

   · 

  5 min read

   · 

  Kate Goodwin
• 

  Immunology and inflammation

  Gilead Continues Diversification Drive With Potential $1.7B Inflammation Pact With LEO

  Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 and IL-13 signaling, which in turn are known inflammatory targets.

  January 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Mergers & acquisitions

  GSK Targets Rare Cancer With $1B+ Acquisition of IDRx

  The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.

  January 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Neuropsychiatric disorders

  AbbVie Absorbs $3.5B Cost of Schizophrenia Flop

  Emraclidine was the centerpiece of AbbVie’s $8.7 billion acquisition of Cerevel in December 2023 but failed two mid-stage trials. Tavapadon, meanwhile, has been a more rewarding asset for the pharma, clearing three Phase III Parkinson’s studies in 2024.

  January 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Mergers & acquisitions

  Johnson & Johnson Makes Major Neuro Play With $14.6B Intra-Cellular Buyout

  Among Intra-Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for major depressive disorder.

  January 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Neuroscience

  Biogen Submits Offer to Buy Embattled Partner Sage

  Biogen’s proposed acquisition comes after two difficult years of regulatory and clinical challenges, during which shares of Sage Therapeutics have fallen by more than 90%.

  January 13, 2025

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Deals

  Lilly Drops Up to $2.5B for Scorpion’s PI3K-inhibitor Molecule

  The multi-billion deal, in which Eli Lilly will acquire Scorpion Therapeutics’ STX-478 program, is a shot in the arm for PI3K treatments, which have had a mixed history over the past few years.

  January 13, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky
• 

  FDA

  5 Novel FDA Approvals Notched in 2024

  Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming particularly in the oncology and neurosciences spaces.

  January 13, 2025

   · 

  7 min read

   · 

  Heather McKenzie